NEW YORK (GBI Research), 3 September 2012 - Pharmaceutical companies are spending increasing amounts on the exploration of innovative drug delivery methods in order to administer medication to patients more effectively and boost efficacy, according to a latest report* from pharmaceutical industry experts GBI Research.
Sophisticated drug delivery systems can cater for patient requirements, or those of the molecule itself. Certain drug delivery systems can promote patient adherence with medication schedules, potentially improving efficacy outcomes and making products more cost effective, thereby providing commercial opportunities for pharmaceutical companies. Drug delivery methods can enable the use of promising molecules which have poor solubility, or require selective delivery to a particular tissue, such as the brain. Drug delivery technologies can enable companies to differentiate their products within crowded therapeutic areas, or improve upon existing drugs. The commercial success of innovative drug delivery technologies is clear, and the driving market competition creates significant positive changes for many patients.
Research is being directed toward drug delivery methods used for oncology treatments, as drug companies study new ways to deliver existing molecules. Reducing drug toxicity in cancer treatment would be a huge medical breakthrough, and may be achieved by reformulating products to remove toxic elements, or by closely targeting drugs to cancer cells to reduce peripheral damage.
A war against needles is also being fought, as diabetes patients hold out hope for new delivery technologies, while current insulin treatments all relying on subcutaneous methods, whether by injection, pen injectors, or insulin pumps. Similarly, specialists are looking at how vaccines may be delivered to mucosal systems rather than intravenously, as these could offer a painless and less invasive alternative to childhood injections.
Failure to understand patient needs can ultimately cause the commercial failure of a product, and drug delivery researchers will therefore benefit from contact with patients, identifying their most pressing needs and developing products around these. However, proof will be needed to back up claims that drug delivery methods are not a waste of valuable R&D funding. For instance, the link between convenience and adherence with medication schedules will come under closer scrutiny in the future, as reimbursement companies will demand clinical data to support the superiority of less frequent dosing regimens.
The global drug delivery market was estimated to be worth $101 billion in 2009, and set to rise to $199 billion in 2016 at a Compound Annual Growth Rate (CAGR) of 10.32%. Individual blockbuster products may earn over $1 billion as a single product.
* Innovation in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
This report provides an overview of the most exciting innovations in drug delivery technologies in major therapeutic areas – oncology, vaccines, diabetes, rheumatology and respiratory diseases.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@gbiresearch.com
